Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin

Apoptosis

Volumn 3, Issue 6, 1998, Pages 439-449

  Cartee, L ^a   Kucera, G L ^a   Willingham, M C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Annexin V; Apoptosis; Caspase; Gemcitabine; Ovarian cancer; Staurosporine

Indexed keywords

EID: 0009977191     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009614703977     Document Type: Article

References (31)

1. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
2. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993; 68: 52-56.
3. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995; 22: 19-25.
4. Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 1995; 19: 849-856.
5. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181-188.
6. Cartee L, Kucera GL. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 1998; 41: 403-412.
7. Allouche M, Bettaieb A, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene 1997; 14: 1837-1845.
8. Srinivasan A, Foster LM, Testa MP, et al. Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis. J Neurosci 1996; 16: 5654-5660.
9. Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271: 31075-31085.
10. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 1997; 45: 923-934.
11. Fornari FA Jr, Jarvis WD, Grant S, et al. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 1994; 5: 723-733.
12. Otto AM, Paddenberg R, Schubert S, Mannherz HG. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996; 122: 603-612.
13. Ozols RF. Ovarian cancer, part II: treatment. Curr Probl Cancer 1992; 16: 61-126.
14. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol 1997; 8: 1045-1048.
15. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82: 349-352.
16. Kumar S. The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol 1997; 29: 393-396.
17. Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Brit Med Bull 1997; 53: 491-508.
18. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-1556.
19. Frey T. Correlated flow cytometric analysis of terminal events in apoptosis reveals the absence of some changes in some model systems. Cytometry 1997; 28: 253-263.
20. Falcieri E, Martelli AM, Bareggi R, Cataldi A, Cocco L. The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem Biophys Res Commun 1993; 193: 13-18.
21. Jarvis WD, Turner A, Grant S. The protein kinase C inhibitor staurosporine potentiates 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 and U937 leukemia cells, resulting in synergistic antileukemic effects. Proc Am Assoc Cancer Res 1993; 35: 189.
22. McNeil C. Ovarian cancer: latest gains establish new battle fronts. J Natl Cancer Inst 1995; 87: 871-873.
23. Hansen HH, Eisenhauer EA, Hansen M, et al. New cytostatic drugs in ovarian cancer. Ann Oncol 1993; 4: 63-70.
24. Oberhammer F, Wilson JW, Dive C, et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993; 12: 3679-3684.
25. Pulkkinen JO, Elomaa L, Joensuu H, et al. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 1996; 122: 214-218.
26. Porter AG, Ng P, Janicke RU. Death substrates come alive. Bioessays 1997; 19: 501-507.
27. Engeland van M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger, CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9.
28. Halicka HD, Seiter K, Feldman EJ, et al. Cell cycle specificity of apoptosis during treatment of leukaemias. Apoptosis 1997; 2: 25-39.
29. Eastman A. Apoptosis: a product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 1993; 121: 160-164.
30. Rouquet N, Carlier K, Briand P, Wiels J, Joulin V. Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Biochem Biophys Res Commun 1996; 229: 27-35.
31. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996; 88: 1308-1314.